Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076731 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Angioletta Lasagna und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. Hauptthemen laut MEDLINE: COVID-19, Virus Diseases, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Fondazione IRCCS Policlinico San Matteo.
Abstract (Originalsprache)
The role and durability of the immunogenicity of the BNT162b2 mRNA vaccine against severe acute respiratory virus 2 (SARS-CoV-2), in cancer patients one year after receiving the third dose have to be elucidated. We have prospectively evaluated the long-term immunogenicity of the third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in 55 patients undergoing active treatment. Neutralizing antibody (NT Ab) titers against Omicron variants and total anti-trimeric S IgG levels were measured one year after the third dose. Heparinized whole-blood samples were used for the assessment of the SARS-CoV-2 interferon-γ release assay (IGRA). Thirty-seven patients (67.3%) showed positive total anti-trimeric S IgG one year after the third dose. Looking at the T-cell response against the spike protein, the frequency of responder patients did not decrease significantly between six and twelve months after the third dose. Finally, less than 20% of cancer patients showed an undetectable NT Ab titer against BA.1 and BA.5 variants of concern (VOCs). Underlying therapies seem to not affect the magnitude or frequency of the immune response. Our work underlines the persistence of humoral and cellular immune responses against BNT162b2 in a cohort of cancer patients one year after receiving the third dose, regardless of the type of underlying therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
- Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
- Microbiology Unit, Hospital Guglielmo da Saliceto, 29121 Piacenza, Italy.
- Department of Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy.
- Department of Clinical, Surgical, Diagnostics and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy.
ORCID-Profile: Angioletta Lasagna, Irene Cassaniti, Giuliana Lo Cascio, Paolo Pedrazzoli
Förderung
- Ministero della Salute
- Fondazione IRCCS Policlinico San Matteo
Zitieren
APA
Lasagna, A., Cassaniti, I., Arena, F., Bergami, F., Percivalle, E., Comolli, G., Sarasini, A., Ferrari, A., Cicognini, D., Schiavo, R., Lo Cascio, G., Pedrazzoli, P., & Baldanti, F. (2023). Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076731
Vancouver
Lasagna A, Cassaniti I, Arena F, Bergami F, Percivalle E, Comolli G, et al. Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076731
BibTeX
@article{Lasagna2023,
author = {Lasagna, Angioletta and Cassaniti, Irene and Arena, Francesca and Bergami, Federica and Percivalle, Elena and Comolli, Giuditta and Sarasini, Antonella and Ferrari, Alessandro and Cicognini, Daniela and Schiavo, Roberta and Lo Cascio, Giuliana and Pedrazzoli, Paolo and Baldanti, Fausto},
title = {Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076731}
}
EUVIMED